Drug updated on 4/18/2024
| Dosage Form | Injection (intravenous; 18.5 MBq/mL to 148 MBq/mL [0.5 mCi/mL to 4 mCi/mL]) |
| Drug Class | Radioactive diagnostic agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.
Summary
- Ga 68 DOTATOC is indicated for use with positron emission tomography (PET) for localizing somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. It has shown superior sensitivity compared to SPECT agents, making it more suitable for in vivo identification of these tumors.
- The study synthesized findings from a total of 10 systematic reviews and meta-analyses on the use and application of Ga 68 DOTATOC.
- In comparison to other tracers such as I-131 MIBG and chemotherapy, Ga 68 DOTATOC demonstrated favorable disease control rates, especially in paragangliomas (PGLs), pheochromocytomas (PCCs), meningiomas, and tumor-induced osteomalacia (TIO). However, hematologic toxicity was identified as a secondary concern.
- For recurrent meningiomas and pituitary carcinomas cases, the use of SSR-targeted PET with Ga 68 DOTATOC enhances diagnostic accuracy while improving radiotherapy planning. This also confirms patient eligibility for PRRT treatment but calls attention to clearer management guidelines due to variations observed across studies.
- Genetic alterations like mutations of SDHB were frequently observed among populations affected by PCCs & PGLs, which could influence treatment responses. Also noted was that advanced or inoperable NET patients showed substantial benefit from Lu-DOTATATE/DOTATOC PRRT treatments, indicating the importance based on disease severity considerations during the treatment selection process.
- Ga 68 DOTA-SSTR PET/CT exhibited higher sensitivity than F18 FDG PET/CT when detecting Tumor Induced Osteomalacia(TIO). Therefore, it should be considered as the first-line imaging modality over others.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Ga 68 DOTATOC Prescribing Information. | 2021 | UIHC PET Imaging Center, Iowa City, IA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. | 2020 | Annals of Oncology |